Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Fexofenadine is a metabolic product of which drug?

Terfenadine. **Explanation:** **Correct Answer: D. Terfenadine** **Mechanism and Concept:** Fexofenadine is the active acid metabolite of **Terfenadine**, a second-generation H1-antihistamine. Terfenadine was originally developed as a non-sedating antihistamine; however, it was found to be a "prodrug" that undergoes extensive first-pass metabolism in the liver via the **CYP3A4** enzyme to form Fexofenadine. The clinical significance lies in safety: Terfenadine itself is cardiotoxic. It blocks delayed rectifier potassium channels ($I_{Kr}$) in the heart, leading to **QT interval prolongation** and the potentially fatal arrhythmia, **Torsades de Pointes**. This occurs especially when its metabolism is inhibited (e.g., by erythromycin or ketoconazole). Fexofenadine, however, provides the same antihistaminic benefits without the cardiotoxic effects, leading to the withdrawal of Terfenadine from most markets. **Analysis of Incorrect Options:** * **A. Loratadine:** It is a prodrug, but its active metabolite is **Desloratadine**. * **B. Astemizole:** Like Terfenadine, it was withdrawn due to QT prolongation. Its active metabolite is **Desmethylastemizole**. * **C. Cetirizine:** It is actually the active metabolite of **Hydroxyzine** (a first-generation antihistamine). **High-Yield NEET-PG Pearls:** * **Active Metabolites:** Remember the pairs: Terfenadine $\rightarrow$ Fexofenadine; Loratadine $\rightarrow$ Desloratadine; Hydroxyzine $\rightarrow$ Cetirizine. * **Cardiotoxicity:** Terfenadine and Astemizole are the classic examples of drugs causing Torsades de Pointes via CYP3A4 interactions. * **P-glycoprotein:** Fexofenadine is a substrate for P-glycoprotein, which limits its entry into the CNS, contributing to its highly non-sedating nature.

Q: If the clearance of a drug equals its renal plasma flow, what does it imply about the drug's handling by the kidneys?

The drug is actively secreted into the renal tubules.. The concept of **Renal Clearance ($CL_r$)** is a measure of the volume of plasma cleared of a drug per unit of time [3]. To understand how a drug is handled by the kidney, we compare its clearance to the **Glomerular Filtration Rate (GFR)** and **Renal Plasma Flow (RPF)**. 1. **Why Option B is Correct:** Normal GFR is approximately **125 mL/min**, while Renal Plasma Flow (RPF) is approximately **650 mL/min**. If a drug's clearance equals the RPF, it means that *all* the plasma passing through the kidney is being stripped of the drug in a single pass [2]. Since only 20% of plasma is filtered at the glomerulus, the remaining 80% must be cleared via **active tubular secretion** in the proximal tubules to reach a clearance value equal to the RPF [1]. 2. **Why Other Options are Incorrect:** * **Option A:** If a drug is actively reabsorbed (like glucose or certain electrolytes), its clearance will be significantly **lower than the GFR** ($<125$ mL/min) [1]. * **Option C:** If a drug undergoes only filtration with no secretion or reabsorption (like **Inulin**), its clearance will **equal the GFR** (~125 mL/min) [3]. **High-Yield NEET-PG Pearls:** * **Inulin Clearance:** The gold standard for measuring GFR ($CL = GFR$) [3]. * **Creatinine Clearance:** Slightly overestimates GFR because it undergoes a small amount of tubular secretion. * **Para-aminohippuric acid (PAH):** The classic example of a drug where clearance equals RPF because it is both filtered and completely secreted [2]. * **Formula:** $Excretion = (Filtration + Secretion) - Reabsorption$. If Clearance > GFR, secretion is occurring [1].

Q: ED50 is a measure of:

Potency. **Explanation:** **Why Potency is Correct:** **Potency** refers to the amount or concentration of a drug required to produce a specific intensity of effect. It is measured by the **ED50 (Median Effective Dose)**, which is the dose required to produce a specified therapeutic response in 50% of the population. On a Dose-Response Curve (DRC), potency is represented by the position of the curve along the X-axis (dose). A drug that achieves ED50 at a lower dose is considered more potent. **Why Other Options are Incorrect:** * **Toxicity:** This is measured by the **TD50** (Median Toxic Dose) or **LD50** (Median Lethal Dose). While ED50 relates to the therapeutic effect, TD50 relates to adverse or lethal effects. * **Safety:** The safety of a drug is determined by the **Therapeutic Index (TI)**, calculated as the ratio of **LD50/ED50**. A higher TI indicates a wider margin of safety. * **Efficacy:** This refers to the maximum effect (Emax) a drug can produce, regardless of dose. On a DRC, efficacy is represented by the height (Y-axis) of the curve. A drug can be highly potent but have low efficacy, or vice versa. **High-Yield Clinical Pearls for NEET-PG:** * **Potency vs. Efficacy:** Efficacy is clinically more important than potency. For example, Furosemide is more efficacious than Chlorothiazide because it can remove more fluid, even if Chlorothiazide requires a smaller dose (higher potency) to start its effect. * **Therapeutic Window:** The range between the minimum effective dose and the maximum tolerated dose. * **Standard Safety Margin:** Calculated as `[(LD1 - ED99) / ED99] × 100`. This is a more rigorous measure of safety than the Therapeutic Index.

Q: The pharmacokinetic properties of a new antihistamine are being studied in normal volunteers during phase I clinical trials. The clearance and half-life of the drug are determined to be 4.0 L/hour and 10 hours, respectively. Which of the following values is the approximate volume of distribution for this drug?

60 L. ### Explanation **1. Why the Correct Answer is Right** The volume of distribution ($V_d$) is a theoretical volume that relates the amount of drug in the body to its concentration in the plasma. To solve this, we use the fundamental pharmacokinetic relationship between **Clearance ($CL$)**, **Half-life ($t_{1/2}$)**, and **Volume of Distribution ($V_d$)**: $$t_{1/2} = \frac{0.693 \times V_d}{CL}$$ Rearranging the formula to solve for $V_d$: $$V_d = \frac{t_{1/2} \times CL}{0.693}$$ **Calculation:** * $CL = 4.0 \text{ L/hr}$ * $t_{1/2} = 10 \text{ hours}$ * $V_d = \frac{10 \times 4.0}{0.693} \approx \frac{40}{0.7} \approx 57.14 \text{ L}$ The value **60 L** (Option D) is the closest approximation. **2. Why the Incorrect Options are Wrong** * **Option A (0.06 L):** This value is physiologically impossible for an adult and likely results from a decimal error in calculation. * **Option B (14 L):** This represents the extracellular fluid volume. A drug with this $V_d$ would be restricted to plasma and interstitial fluid. * **Option C (45 L):** This represents total body water (TBW). While closer, it does not match the mathematical result derived from the provided clearance and half-life. **3. Clinical Pearls & High-Yield Facts for NEET-PG** * **$V_d$ Interpretation:** If $V_d$ is low (approx. 3–5 L), the drug is confined to the vascular compartment (e.g., Warfarin). If $V_d$ is high (>42 L), the drug is sequestered in tissues (e.g., Digoxin, Chloroquine). * **Loading Dose:** $V_d$ is the primary determinant of the **Loading Dose** ($LD = V_d \times C_{ss}$). * **Clearance:** $CL$ is the primary determinant of the **Maintenance Dose**. * **Half-life:** It takes approximately **4 to 5 half-lives** to reach steady-state concentration ($C_{ss}$) and the same amount of time to eliminate the drug from the body after stopping.

Question 1

A drug that binds to a receptor at a site distinct from the active site and alters the affinity of the receptor for the endogenous ligand is a:

Accepted Answer

Allosteric modulator

Answer

Competitive antagonist

Answer

Inverse agonist

Answer

Partial agonist

Question 2

According to the two-state receptor theory, which of the following statements BEST explains the term "agonists"?

Accepted Answer

Strong affinity for the receptor in the active state (Ra)

Answer

Strong affinity for the receptor in the inactive state (Ri)

Answer

Equal affinity for Ra and Ri

Answer

Slightly more affinity for Ra than Ri

Question 3

Which drug does not follow nonlinear dose-dependent saturation kinetics?

Accepted Answer

Paracetamol

Answer

Salicylates

Answer

Phenytoin

Answer

Ethanol

Question 4

Fexofenadine is a metabolic product of which drug?

Accepted Answer

Terfenadine

Answer

Loratadine

Answer

Astemizole

Answer

Cetirizine

Question 5

Gentamicin has a half-life of 2-3 hours in plasma, but it accumulates in the kidney, prolonging its half-life to 53 hours. What is this prolonged half-life called?

Accepted Answer

Terminal half-life

Answer

Secondary half-life

Answer

Zero order half-life

Answer

First order half-life

Question 6

If the clearance of a drug equals its renal plasma flow, what does it imply about the drug's handling by the kidneys?

Accepted Answer

The drug is actively secreted into the renal tubules.

Answer

The drug is actively reabsorbed in the renal tubules.

Answer

The drug undergoes neither significant secretion nor reabsorption in the renal tubules.

Answer

None of the above.

Question 7

Which of the following is true for the receptor action of a drug?

Accepted Answer

An antagonist has affinity but no intrinsic activity for the receptor.

Answer

An antagonist has both intrinsic activity and affinity for the receptor.

Answer

A partial antagonist has no affinity or intrinsic activity for the receptor.

Answer

Intrinsic activity and affinity are not important for drug action.

Question 8

ED50 is a measure of:

Accepted Answer

Potency

Answer

Toxicity

Answer

Safety

Answer

Efficacy

Question 9

Which of the following is NOT an example of nonlinear kinetics?

Accepted Answer

Metabolism of diazepam

Answer

Metabolism of phenytoin

Answer

Biliary secretion of bromosulfthalein (BSP)

Answer

Glomerular filtration of naproxen

Question 10

The pharmacokinetic properties of a new antihistamine are being studied in normal volunteers during phase I clinical trials. The clearance and half-life of the drug are determined to be 4.0 L/hour and 10 hours, respectively. Which of the following values is the approximate volume of distribution for this drug?

Accepted Answer

60 L

Answer

0.06 L

Answer

14 L

Answer

45 L

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?